Simonelli, MMSimonelliGarralda, EEGarraldaEskens, FFEskensGil-Martin, MMGil-MartinYen, C-JC-JYenObermannova, RRObermannovaChao, YYChaoLonardi, SSLonardiMelichar, BBMelicharMoreno, VVMorenoYu, M-LM-LYuBongiovanni, AABongiovanniCalvo, EECalvoRottey, SSRotteyMachiels, J-PJ-PMachielsGonzalez-Martin, AAGonzalez-MartinPaz-Ares, LLPaz-AresChang, C-LC-LChangMason, WWMasonCHIA-CHI LINReardon, D AD AReardonVieito, MMVieitoSantoro, AASantoroMeng, RRMengAbbadessa, GGAbbadessaMenas, FFMenasLee, HHLeeLiu, QQLiuCombeau, CCCombeauTernes, NNTernesZiti-Ljajic, SSZiti-LjajicMassard, CCMassard2024-01-122024-01-122022-1020597029https://scholars.lib.ntu.edu.tw/handle/123456789/638444The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there are no data on its efficacy in solid tumors. This phase I/II study (NCT03637764) assessed the safety and activity of isatuximab plus atezolizumab (Isa + Atezo), an anti-programmed death-ligand 1 (PD-L1) antibody, in patients with immunotherapy-naive solid tumors: epithelial ovarian cancer (EOC), glioblastoma (GBM), hepatocellular carcinoma (HCC), and squamous cell carcinoma of the head and neck (SCCHN).enanti-CD38; anti-PD-L1; atezolizumab; isatuximab; solid tumors[SDGs]SDG3journal article10.1016/j.esmoop.2022.100562359871652-s2.0-85136683326https://api.elsevier.com/content/abstract/scopus_id/85136683326